Love your thinking. Unfortunately ethics committees might not approve.
Unless I am missing your sarcasm. They are currently conducting Phase I/II trials, so these are in healthy human patients. Terry I think you're very eager, but I would suggest extending your timeframes by a few months/years for anything definitive on the Herpes immunisation. Whilst you might see a response in days, you would want to see long term coverage.
The next bump on SP might come with FDA, although I would suspect that might have been taken into consideration on the valuation. It will be interesting to see if we some information on sales from Europe on a 6month cycle.
admedus, page-22
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |